We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,953.00
Bid: 6,953.00
Ask: 6,955.00
Change: -57.00 (-0.81%)
Spread: 2.00 (0.03%)
Open: 7,001.00
High: 7,172.00
Low: 6,943.00
Yest. Close: 7,010.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 2-Galenica to buy biotech firm Relypsa for $1.5 bln, ahead of split

* Deal brings worldwide rights to potassium medicine * Builds up Vifor Pharma unit ahead of 2017 split * Galenica shares down 7 percent (Adds analyst reaction, latest shares, advisers) By Sylwia Lasek and Ben Hirschler July 21 (Reuters) - Galenica has agreed to buy Relyp

21 Jul 16 08:30

UPDATE 1-Galenica to buy biotech firm Relypsa for $1.5 bln before break-up

(Adds details on deal, more on drug and competitive landscape) By Sylwia Lasek July 21 (Reuters) - Galenica has agreed to buy U.S. biotech firm Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group. Galenica, which

21 Jul 16 07:30

Your inhaler's watching you: drugmakers race for smart devices

* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung

20 Jul 16 12:42

Judge refuses to block generic versions of AstraZeneca's Crestor

By Brendan Pierson July 19 (Reuters) - A U.S. judge on Tuesday refused to issue a temporary restraining order blocking the approval of new generic versions of AstraZeneca's blockbuster cholesterol drug Crestor in the United States. U.S. District Judge Randolph Moss in Washington, D.C.

19 Jul 16 22:58

UPDATE 2-U.S. FDA panel backs Valeant psoriasis drug with risk program

(Adds comments from panelists) By Toni Clarke July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee t

19 Jul 16 20:22

UPDATE 1-U.S. FDA panel backs Valeant psoriasis drug with risk management

(Adds background on studies, paragraphs 3, 4) July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the

19 Jul 16 19:41

U.S. FDA panel backs Valeant psoriasis drug with risk management

July 19 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesd

19 Jul 16 19:25

AstraZeneca's Qtern Gets European Approval For Type 2 Diabetes

19 Jul 16 13:22

LONDON MARKET OPEN: ARM Leads Rising Market But Tour Operators Down

18 Jul 16 07:32

AstraZeneca celebrates success in latest Tagrisso trial

(ShareCast News) - AstraZeneca announced on Monday that the Phase III AURA3 trial has met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The FTSE 100 pharmaceutical giant said the AURA3 randomised trial assessed

18 Jul 16 07:06

TOP NEWS: AstraZeneca Gets Strong Results From Tagrisso Trial

18 Jul 16 06:28

UPDATE 2-Valeant psoriasis drug's suicide risk hard to assess -FDA Staff

(Adds analyst comment, background) July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to a preliminary review by the U.S. Food

15 Jul 16 13:30

UPDATE 1-Valeant psoriasis drug's suicide risk hard to assess -FDA Staff

(Updates with details from FDA review) July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, a preliminary review by the U.S. Food and Drug

15 Jul 16 12:59

Valeant psoriasis drug safety challenging to assess -FDA Staff

July 15 (Reuters) - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries several potential risks that are challenging to assess due to limited controlled data, a preliminary review by the U.S. Food and Drug Administration. The review com

15 Jul 16 12:26

BROKER RATINGS SUMMARY: Goldman Sachs Cuts ASOS To Neutral From Buy

14 Jul 16 08:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.